SRN-101 / Siren Biotech - LARVOL DELTA

SRN-101 universal AAV gene therapy for solid tumors (ASGCT 2025) - "Supported by the Translational Science Committee"

Gene therapy • Gene Therapies • Oncology • Solid Tumor

Siren Biotechnology to Present Universal AAV Immuno-Gene Therapy Data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire) - "Siren Biotechnology Inc...announced that it will present new scientific data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 13–17 in New Orleans, LA."

Clinical data • Glioma • Solid Tumor

Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA (GlobeNewswire) - "Siren Biotechnology...today revealed its lead asset, SRN-101, for the treatment of high-grade gliomas. The FDA granted both Orphan Drug and Rare Pediatric Disease designations to SRN-101, supporting its development as a new therapy for patients with high-grade gliomas and pediatric-type diffuse high-grade gliomas, respectively, some of the most aggressive brain cancers with few therapeutic options."

FDA event • Orphan drug • Glioma